176 results on '"Lenting, Peter J."'
Search Results
2. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis
3. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy
4. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models
5. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
6. von Willebrand factor: from figurant to main character in the scene of inflammation
7. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
8. Cerebral Microbleeds During Transcatheter Aortic Valve Replacement: A Prospective Magnetic Resonance Imaging Cohort
9. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
10. Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria
11. Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells
12. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
13. von Willebrand disease: what does the future hold?
14. Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates
15. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab
16. Von Willebrand factor: how unique structural adaptations support and coordinate its complex function
17. Genotype-Dependent Response to Desmopressin in Hemophilia A and Proposal of a Predictive Response Score
18. An inhibitory single-domain antibody against protein Z-dependent protease inhibitor promotes thrombin generation in hemophilia A and FXI deficiency
19. Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs
20. In vivo modulation of a dominant‐negative variant in mouse models of von Willebrand disease type 2A
21. TaSER: Combining forces to stop the clot
22. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
23. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
24. A hemophilia A mouse model for the in vivo assessment of emicizumab function
25. Laboratory monitoring of hemophilia A treatments: new challenges
26. A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A
27. A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor
28. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
29. Plasmin-Cleaved Von Willebrand Factor As a Biomarker for Microvascular Thrombosis
30. Emicizumab and thrombosis: The story so far
31. Antibodies in the Treatment of Haemophilia A—A Biochemical Perspective
32. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
33. A FVIII-Mimetic Bispecific Antibody with an Embedded Self-Regulation Mechanism Reduces the Risk of Prothrombotic Events for the Treatment of Haemophilia a
34. A factor VIII–nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation
35. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets
36. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
37. A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammation—Brief Report
38. Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi
39. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
40. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab
41. A nanobody against the von Willebrand factor A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired von Willebrand disease
42. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
43. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis
44. Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X
45. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
46. A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient
47. Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice
48. Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpurain mice
49. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices
50. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.